Log in

CVE:SVASernova Stock Price, Forecast & News

+0.01 (+5.26 %)
(As of 05/29/2020 04:00 PM ET)
Today's Range
Now: C$0.20
50-Day Range
MA: C$0.16
52-Week Range
Now: C$0.20
Volume324,900 shs
Average Volume321,630 shs
Market CapitalizationC$39.19 million
P/E RatioN/A
Dividend YieldN/A
Sernova Corp., a clinical-stage regenerative medicine therapeutics company, focuses on the development and commercializing of its proprietary Cell Pouch and associated technologies, including therapeutic cells and local immune protection. The company is developing a Cell Pouch system that is in Phase I/II clinical trial for the treatment of type-1 diabetes. Its Cell Pouch system is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells for the treatment of chronic diseases, such as hemophilia A and thyroid diseases. Sernova Corp. is headquartered in London, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.46 out of 5 stars

Industry, Sector and Symbol

Industry Diagnostics & Research



Sales & Book Value

Annual SalesN/A
Cash FlowC$0.02 per share
Book ValueC$0.02 per share



Market CapC$39.19 million
Next Earnings Date6/26/2020 (Estimated)

Receive SVA News and Ratings via Email

Sign-up to receive the latest news and ratings for SVA and its competitors with MarketBeat's FREE daily newsletter.

Sernova (CVE:SVA) Frequently Asked Questions

How has Sernova's stock been impacted by COVID-19 (Coronavirus)?

Sernova's stock was trading at C$0.15 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SVA shares have increased by 37.9% and is now trading at C$0.20. View which stocks have been most impacted by Coronavirus.

When is Sernova's next earnings date?

Sernova is scheduled to release its next quarterly earnings announcement on Friday, June 26th 2020. View our earnings forecast for Sernova.

How were Sernova's earnings last quarter?

Sernova Corp. (CVE:SVA) issued its earnings results on Thursday, March, 19th. The company reported ($0.01) earnings per share for the quarter. View Sernova's earnings history.

Has Sernova been receiving favorable news coverage?

News articles about SVA stock have trended extremely negative recently, InfoTrie reports. The research firm rates the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Sernova earned a media sentiment score of -5.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutSernova.

Who are some of Sernova's key competitors?

What other stocks do shareholders of Sernova own?

What is Sernova's stock symbol?

Sernova trades on the Canadian Venture Exchange (CVE) under the ticker symbol "SVA."

How do I buy shares of Sernova?

Shares of SVA and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Sernova's stock price today?

One share of SVA stock can currently be purchased for approximately C$0.20.

How big of a company is Sernova?

Sernova has a market capitalization of C$39.19 million.

What is Sernova's official website?

The official website for Sernova is www.sernova.com.

How can I contact Sernova?

Sernova's mailing address is 700 Collip Cir Suite 114, LONDON, ON N6G 4X8, Canada. The company can be reached via phone at +1-519-8585184.

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.